Drugs / Teniposide
Teniposide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VUMON | — | 1992-07-14 | fda.gov ↗ |
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004916 | Feb 1999 → Oct 2002 | lymphoma | Northwestern University | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06758700 | Feb 2025 → Jun 2026 overdue | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07188441 | Aug 2024 → Dec 2026 expected | central nervous system germ cell tumor | Chengcheng Guo | Recruiting | No outcome recorded |
| Phase 2 | NCT07583511 | Feb 2024 → May 2027 expected | small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00186875 | Nov 2003 → Aug 2016 | acute lymphoblastic leukemia, lymphoblastic lymphoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00004231 | Oct 1999 → Aug 2006 | lymphoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00002531 | Jan 1993 → ? | leukemia | Johann Wolfgang Goethe University Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07185373 | Oct 2025 → Sep 2028 expected | primary central nervous system lymphoma | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06038422 | Sep 2023 → Sep 2024 | hemophagocytic syndrome, refractory malignant neoplasm | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT01960192 | Jun 2012 → Jun 2016 | primary central nervous system lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT00853008 | Jan 2003 → Nov 2012 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00199056 | Oct 1999 → Nov 2003 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| Phase 4 | NCT00199095 | Feb 1997 → Jun 2003 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| Phase 4 | NCT00199069 | Apr 1993 → Jan 1999 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07074470 | Jan 2025 → Jan 2030 expected | primary central nervous system lymphoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT06048107 | Oct 2023 → Sep 2024 | hemophagocytic syndrome | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT01700946 Comparator | Apr 2013 → Jul 2021 | B-cell childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01430013 Background | Jun 2011 → Nov 2015 | T-cell non-Hodgkin lymphoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00184041 Background | Jul 2004 → Dec 2011 | adult acute lymphoblastic leukemia | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT01290120 Background | Nov 2002 → Jun 2014 | Burkitt lymphoma | Northern Italy Leukemia Group | Completed | No outcome recorded |
| Phase 3 | NCT00187083 Background | Feb 1997 → Dec 2003 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00199004 Background | Apr 2004 → Mar 2009 | adult acute lymphoblastic leukemia | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00198991 Background | Apr 2003 → Jun 2011 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| — | NCT00343369 Background | Jan 2003 → ? | leukemia | University Medical Center Hamburg-Eppendorf | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | teniposide | “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗19“Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)” NCT06038422 ↗ “Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone” NCT01430013 ↗ “FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt” NCT01960192 ↗ “Temsirolimus, Teniposide, Thioguanine” NCT02788201 ↗ |
| Known as | NSC-122819 | ChEMBL registry synonym — accepted as the source's own label CHEMBL452231 ↗ |
| Known as | Teniposido | ChEMBL registry synonym — accepted as the source's own label CHEMBL452231 ↗ |
| Known as | VM-26 | “teniposide (VM-26) IV over 1 hour” NCT00002531 ↗ |
| Known as | Vumon | ChEMBL registry synonym — accepted as the source's own label CHEMBL452231 ↗ |
| Modality | Small molecule | — CHEMBL452231 ↗ |
| Route | Intravenous | “teniposide (VM-26) IV over 1 hour” NCT00002531 ↗ |